Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Avidity Biosciences, Inc. - Common Stock
(NQ:
RNA
)
69.65
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Avidity Biosciences, Inc. - Common Stock
RNA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Avidity Biosciences, Inc. is Fair to Shareholders
October 28, 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights
From
Halper Sadeh LLC
Via
GlobeNewswire
RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders
October 28, 2025
From
Halper Sadeh LLC
Via
Business Wire
Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA
October 27, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Essential Utilities, Inc. (NYSE – WTRG), Cadence Bank (NYSE – CADE), Avidity Biosciences, Inc. (Nasdaq – RNA), Plymouth Industrial REIT, Inc. (NYSE – PLYM)
October 27, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
RNA STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF AVIDITY BIOSCIENCES, INC. IS FAIR TO SHAREHOLDERS
October 26, 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
From
Halper Sadeh LLC
Via
GlobeNewswire
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
August 19, 2024
Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials.
Via
MarketBeat
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
September 13, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food...
Via
FinancialNewsMedia
Avidity Biosciences (NASDAQ: RNA) Posts Positive Phase 1/2 MARINA Data on AOC 1001, Announcing the First Successful Delivery of RNA to Muscle
December 14, 2022
Avidity Biosciences, Inc. (NASDAQ: RNA) is engaged as a biopharmaceutical company, which is focused on developing a new class of
Via
Spotlight Growth
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.